{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:01:20Z","timestamp":1771671680797,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89905","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:18:32Z","timestamp":1755015512000},"source":"Crossref","is-referenced-by-count":1,"title":["Anti-TIF1-Gamma Autoantibodies-Positive Juvenile Dermatomyositis Associated With Interstitial Lung Disease: A Case Report"],"prefix":"10.7759","author":[{"given":"Ricardo","family":"Cid-Puente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac A","family":"Carreon-Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Herrera-VanOostdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/56ilob","article-title":"Juvenile dermatomyositis. Where are we now?","volume":"40","author":"McCann LJ","year":"2022","unstructured":"McCann LJ, Livermore P, Wilkinson MG, Wedderburn LR. Juvenile dermatomyositis. Where are we now?. Clin Exp Rheumatol. 2022, 40:394-403. 10.55563\/clinexprheumatol\/56ilob","journal-title":"Clin Exp Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/children11091046","article-title":"Advances in juvenile dermatomyositis: pathophysiology, diagnosis, treatment and interstitial lung diseases--a narrative review","volume":"11","author":"Kobayashi I","year":"2024","unstructured":"Kobayashi I. Advances in juvenile dermatomyositis: pathophysiology, diagnosis, treatment and interstitial lung diseases--a narrative review. Children (Basel). 2024, 11:1046. 10.3390\/children11091046","journal-title":"Children (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4078\/jrd.2022.29.1.14","article-title":"Juvenile dermatomyositis","volume":"29","author":"Rhim JW","year":"2022","unstructured":"Rhim JW. Juvenile dermatomyositis. J Rheum Dis. 2022, 29:14-21. 10.4078\/jrd.2022.29.1.14","journal-title":"J Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5513544","article-title":"The significance of autoantibodies in juvenile dermatomyositis","volume":"2021","author":"Kwiatkowska D","year":"2021","unstructured":"Kwiatkowska D, Reich A. The significance of autoantibodies in juvenile dermatomyositis. Biomed Res Int. 2021, 2021:5513544. 10.1155\/2021\/5513544","journal-title":"Biomed Res Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_188_22","article-title":"Clinical significance of myositis-specific and myositis-associated antibody profiles in dermatomyositis","volume":"14","author":"Babu AK","year":"2023","unstructured":"Babu AK, Mizaj Z, Thomas J, Chacko M. Clinical significance of myositis-specific and myositis-associated antibody profiles in dermatomyositis. Indian Dermatol Online J. 2023, 14:55-60. 10.4103\/idoj.idoj_188_22","journal-title":"Indian Dermatol Online J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg IE","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al.. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017, 69:2271-82. 10.1002\/art.40320","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis -- (first of two parts)","volume":"292","author":"Bohan A","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis -- (first of two parts). N Engl J Med. 1975, 292:344-7. 10.1056\/NEJM197502132920706","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-024-00658-2","article-title":"Juvenile dermatomyositis: updates in pathogenesis and biomarkers, current treatment, and emerging targeted therapies","volume":"27","author":"Kim H","year":"2025","unstructured":"Kim H. Juvenile dermatomyositis: updates in pathogenesis and biomarkers, current treatment, and emerging targeted therapies. Paediatr Drugs. 2025, 27:57-72. 10.1007\/s40272-024-00658-2","journal-title":"Paediatr Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.12.053","article-title":"Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity","volume":"195","author":"Pachman LM","year":"2018","unstructured":"Pachman LM, Khojah AM. Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity. J Pediatr. 2018, 195:16-27. 10.1016\/j.jpeds.2017.12.053","journal-title":"J Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0871-4","article-title":"Juvenile dermatomyositis--clinical phenotypes","volume":"21","author":"Li D","year":"2019","unstructured":"Li D, Tansley SL. Juvenile dermatomyositis--clinical phenotypes. Curr Rheumatol Rep. 2019, 21:74. 10.1007\/s11926-019-0871-4","journal-title":"Curr Rheumatol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02599-9","article-title":"Clinical nomogram assisting in discrimination of juvenile dermatomyositis-associated interstitial lung disease","volume":"24","author":"Hu M","year":"2023","unstructured":"Hu M, Shen C, Zheng F, et al.. Clinical nomogram assisting in discrimination of juvenile dermatomyositis-associated interstitial lung disease. Respir Res. 2023, 24:286. 10.1186\/s12931-023-02599-9","journal-title":"Respir Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae182","article-title":"TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients","volume":"63","author":"Nguyen HD","year":"2024","unstructured":"Nguyen HD, Jouen F, D\u00e9chelotte B, et al.. TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients. Rheumatology (Oxford). 2024, 63:e281-4. 10.1093\/rheumatology\/keae182","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081725","article-title":"Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies","volume":"10","author":"Okiyama N","year":"2021","unstructured":"Okiyama N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med. 2021, 10:1725. 10.3390\/jcm10081725","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfab108","article-title":"Myositis antibodies and interstitial lung disease","volume":"7","author":"Basuita M","year":"2022","unstructured":"Basuita M, Fidler LM. Myositis antibodies and interstitial lung disease. J Appl Lab Med. 2022, 7:240-58. 10.1093\/jalm\/jfab108","journal-title":"J Appl Lab Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103464","article-title":"Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case based comprehensive review","volume":"22","author":"Kilinc OC","year":"2023","unstructured":"Kilinc OC, Ugurlu S. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case based comprehensive review. Autoimmun Rev. 2023, 22:103464. 10.1016\/j.autrev.2023.103464","journal-title":"Autoimmun Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino DF","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015, 72:449-55. 10.1016\/j.jaad.2014.12.009","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00754-y","article-title":"Juvenile dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective","volume":"20","author":"Boros C","year":"2022","unstructured":"Boros C, McCann L, Simou S, et al.. Juvenile dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective. Pediatr Rheumatol Online J. 2022, 20:102. 10.1186\/s12969-022-00754-y","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2024869","article-title":"Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis","volume":"2020","author":"Li Y","year":"2020","unstructured":"Li Y, Li Y, Wu J, et al.. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis. J Immunol Res. 2020, 2020:2024869. 10.1155\/2020\/2024869","journal-title":"J Immunol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/395620-anti-tif1-gamma-autoantibodies-positive-juvenile-dermatomyositis-associated-with-interstitial-lung-disease-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:18:32Z","timestamp":1755015512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/395620-anti-tif1-gamma-autoantibodies-positive-juvenile-dermatomyositis-associated-with-interstitial-lung-disease-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.89905","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}